Genitourinary Cancers

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

Combining nivolumab with the angiogenesis inhibitor tivozanib led to a high response rate and durable disease control in patients with metastatic renal cell carcinoma, a preliminary open-label study showed.

Paula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

Sumanta Kumar Pal, MD, discusses potential developments with vaccines and CRISPR/Cas9 technology coming down the pipeline in renal cell carcinoma.

Rupal S. Bhatt, MD, PhD, discusses the discovery of HHLA2/KIR3DL3, a novel therapeutic immune checkpoint pathway in renal cell carcinoma.

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving yet relevant role of surgery in renal cell carcinoma.

Robert G. Uzzo, MD, MBA, FACS, discusses the evolving role of surgery in metastatic kidney cancer.

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.

Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.